Impact of omega-3 supplementation on children and adolescents patients with cystic fibrosis: A systematic review and meta-analysis of randomized-controlled trials.
Study design (if review, criteria of inclusion for studies)
Systematic review
Participants
Randomized controlled studies (RCTs) on young patients with CF.
Interventions
Omega-3 supplementation.
Outcome measures
Levels of docosahexaenoic acid, eicosapentaenoic acid, arachidonic acid, C-receptive protein (CRP); forced expiratory volume 1, forced vital capacity, anthropometric parameters.
Main results
A meta-analysis of 12 the eligible studies was performed. Findings of the study showed that omega-3 supplementation significantly increased the levels of docosahexaenoic acid (weighted mean [WMD]: 2.06%, 95% confidence interval [CI]: 1.29, 2.82, pâ<â0.001) and eicosapentaenoic acid (WMD: 0.32%, 95% CI: 0.15, 0.48, pâ<â0.001) as well as decreased arachidonic acid (WMD: -0.78%, 95% CI: -1.50, -0.05, pâ=â0.035) and C-receptive protein (CRP) (WMD: -3.76âmg/L, 95% CI: -7.42, -0.10, pâ=â0.044) especially when used in higher doses and for a longer period of time compared to the control group. However, no significant effect was observed on other factors including forced expiratory volume 1, forced vital capacity as well as anthropometric parameters. In addition, high heterogeneity was reported for all fatty acids, but heterogeneity was low and nonsignificant for other variables.
Authors' conclusions
The finding showed that in pediatric patients with CF, omega-3 supplementation showed benefits only in plasma fatty acid profile and serum CRP.